Real-World Outcomes of Tisagenlecleucel and Consolidative Hematopoietic Cell Transplantation in Pediatric Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Background/Objectives: Chimeric antigen receptor (CAR) T-cell therapy induces high remission rates in pediatric relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but the durability of remission and the role of consolidative hematopoietic cell transplantation (HCT) in heavily pretreated patients remain unresolved. We evaluated real-world outcomes of CAR T-cell therapy and the feasibility of consolidative HCT. Methods: We retrospectively analyzed 30 children and adolescents with R/R B-ALL who received commercial tisagenlecleucel at a single center. Survival outcomes were compared according to consolidative HCT using a time-dependent Cox model to account for immortal-time bias. Results: Of the 30 patients, 18 (60.0%) had undergone prior allogeneic HCT and 19 (63.3%) had a high disease burden. The 1-month overall response rate was 73.3%, with measurable residual disease-negative remission in 21 patients (95.5% of responders). With a median follow-up of 19.5 months, the 1-year event-free survival (EFS) and overall survival (OS) were 57.2 ± 9.6% and 55.5 ± 9.8%, respectively. One-year relapse-free survival among responders was 77.9 ± 9.9% (67.5 ± 17.2% when censored at HCT). Patients with ≥2 prior relapses had significantly inferior EFS and OS. Twelve of 22 responders (54.5%) underwent consolidative HCT, including 6 who had prior transplantations, with no subsequent relapse; however, no statistically significant survival advantage was observed, and transplanted responders had fewer prior relapses than those who were not transplanted. Conclusions: Treatment failure occurred mainly in patients who did not achieve remission. Consolidative HCT, including second transplantation, was feasible, but its benefit remains uncertain, and which responders require consolidation remains to be defined.
Authors
- Bin Cho (ORCID: https://orcid.org/0000-0001-6675-695X)
- Suejung Jo
- Nack‐Gyun Chung (ORCID: https://orcid.org/0000-0003-4855-390X)
- Jae Won Yoo (ORCID: https://orcid.org/0000-0001-7970-1691)
- Jae Wook Lee (ORCID: https://orcid.org/0000-0002-0735-0287)
- Seongkoo Kim
Institutions
- The Catholic University of Korea Incheon St. Mary's Hospital (KR)
- Incheon Catholic University (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Cancers
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3390/cancers18223700
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00